Page 810 - Williams Hematology ( PDFDrive )

784 Part VI: The Erythrocyte Chapter 49: Disorders of Hemoglobin Structure: Sickle Cell Anemia and Related Abnormalities 785

179. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al: Associated risk factors for silent cerebral 210. Powars DR, Elliott-Mills DD, Chan L, et al: Chronic renal failure in sickle cell disease:
infarcts in sickle cell anemia: Low baseline hemoglobin, sex, and relative high systolic Risk factors, clinical course, and mortality. Ann Intern Med 115(8):614–620, 1991.
blood pressure. Blood 119(16):3684–3690, 2012. 211. Powars DR, Chan LS, Hiti A, et al: Outcome of sickle cell anemia: A 4-decade observa-
180. Hulbert ML, McKinstry RC, Lacey JL, et al: Silent cerebral infarcts occur despite regular tional study of 1056 patients. Medicine (Baltimore) 84(6):363–376, 2005.
blood transfusion therapy after first strokes in children with sickle cell disease. Blood 212. Scheinman J: Sickle Cell Nephropathy. Williams & Wilkins, Boston, 1994.
117(3):772–779, 2011. 213. Sharpe CC, Thein SL: Sickle cell nephropathy—A practical approach. Br J Haematol
181. Prohovnik I, Pavlakis SG, Piomelli S, et al: Cerebral hyperemia, stroke, and transfusion 155(3):287–297, 2011.
in sickle cell disease. Neurology 39(3):344–348, 1989. 214. Huang SH, Sharma AP, Yasin A, et al: Hyperfiltration affects accuracy of creatinine
182. Wang WC: The pathophysiology, prevention, and treatment of stroke in sickle cell dis- eGFR measurement. Clin J Am Soc Nephrol 6(2):274–280, 2011.
ease. Curr Opin Hematol 14(3):191–197, 2007. 215. McKie KT, Hanevold CD, Hernandez C, et al: Prevalence, prevention, and treatment of
183. Switzer JA, Hess DC, Nichols FT, et al: Pathophysiology and treatment of stroke in microalbuminuria and proteinuria in children with sickle cell disease. J Pediatr Hema-
sickle-cell disease: Present and future. Lancet Neurol 5(6):501–512, 2006. tol Oncol 29(3):140–144, 2007.
184. Powars D, Adams RJ, Nichols FT, et al: Delayed intracranial hemorrhage following cere- 216. Kanso AA, Hassan NMA, Badr KF: Microvascular and Macrovascular Diseases of the
bral infarction in sickle cell anemia. J Assoc Acad Minor Phys 1(3):79–82, 1990. Kidney, ed 8. WB Saunders, Philadelphia, 2007.
185. Diggs LW, Brookoff D: Multiple cerebral aneurysms in patients with sickle cell disease. 217. Mantadakis E, Cavender JD, Rogers ZR, et al: Prevalence of priapism in children and
South Med J 86(4):377–379, 1993. adolescents with sickle cell anemia. J Pediatr Hematol Oncol 21(6):518–522, 1999.
186. Anson JA, Koshy M, Ferguson L, et al: Subarachnoid hemorrhage in sickle-cell disease. 218. Fowler JE Jr, Koshy M, Strub M, et al: Priapism associated with the sickle cell hemoglo-
J Neurosurg 75(4):552–558, 1991. binopathies: Prevalence, natural history and sequelae. J Urol 145(1):65–68, 1991.
187. Oyesiku NM, Barrow DL, Eckman JR, et al: Intracranial aneurysms in sickle-cell ane- 219. Emond AM, Holman R, Hayes RJ, et al: Priapism and impotence in homozygous sickle
mia: Clinical features and pathogenesis. J Neurosurg 75(3):356–363, 1991. cell disease. Arch Intern Med 140(11):1434–1437, 1980.
188. Preul MC, Cendes F, Just N, et al: Intracranial aneurysms and sickle cell anemia: Mul- 220. Adeyoju AB, Olujohungbe AB, Morris J, et al: Priapism in sickle-cell disease; inci-
tiplicity and propensity for the vertebrobasilar territory. Neurosurgery 42(5):971–977; dence, risk factors and complications-an international multicentre study. BJU Int 90(9):
discussion 977–978, 1998. 898–902, 2002.
189. O’Driscoll S, Height SE, Dick MC, et al: Serum lactate dehydrogenase activity as a 221. Olujohungbe A, Burnett AL: How I manage priapism due to sickle cell disease. Br J
biomarker in children with sickle cell disease. Br J Haematol 140(2):206–209, 2008. Haematol 160(6):754–765, 2013.
190. Miller ST, Macklin EA, Pegelow CH, et al: Silent infarction as a risk factor for overt 222. Olujohungbe AB, Adeyoju A, Yardumian A, et al: A prospective diary study of stut-
stroke in children with sickle cell anemia: A report from the Cooperative Study of Sickle tering priapism in adolescents and young men with sickle cell anemia: Report of an
Cell Disease. J Pediatr 139(3):385–390, 2001. international randomized control trial—the priapism in sickle cell study. J Androl
191. Pegelow CH, Macklin EA, Moser FG, et al: Longitudinal changes in brain magnetic 32(4):375–382, 2011.
resonance imaging findings in children with sickle cell disease. Blood 99(8):3014–3018, 223. Siegel JF, Rich MA, Brock WA: Association of sickle cell disease, priapism, exchange
2002. transfusion and neurological events: ASPEN syndrome. J Urol 150(5 Pt 1):1480–1482,
192. Kirkham FJ, Hewes DK, Prengler M, et al: Nocturnal hypoxaemia and central-nervous- 1993.
system events in sickle-cell disease. Lancet 357(9269):1656–1659, 2001. 224. Field JJ, Austin PF, An P, et al: Enuresis is a common and persistent problem among
193. Kinney TR, Sleeper LA, Wang WC, et al: Silent cerebral infarcts in sickle cell ane- children and young adults with sickle cell anemia. Urology 72(1):81–84, 2008.
mia: A risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 225. Jordan SS, Hilker KA, Stoppelbein L, et al: Nocturnal enuresis and psychosocial prob-
103(3):640–645, 1999. lems in pediatric sickle cell disease and sibling controls. J Dev Behav Pediatr 26(6):
194. Moser FG, Miller ST, Bello JA, et al: The spectrum of brain MR abnormalities in sickle- 404–411, 2005.
cell disease: A report from the Cooperative Study of Sickle Cell Disease. AJNR Am J 226. Barakat LP, Smith-Whitley K, Schulman S, et al: Nocturnal enuresis in pediatric sickle
Neuroradiol 17(5):965–972, 1996. cell disease. J Dev Behav Pediatr 22(5):300–305, 2001.
195. Strouse JJ, Hulbert ML, DeBaun MR, et al: Primary hemorrhagic stroke in children 227. Almeida A, Roberts I: Bone involvement in sickle cell disease. Br J Haematol
with sickle cell disease is associated with recent transfusion and use of corticosteroids. 129(4):482–490, 2005.
Pediatrics 118(5):1916–1924, 2006. 228. Kim SK, Miller JH: Natural history and distribution of bone and bone marrow infarc-
196. Adams RJ, Kutlar A, McKie V, et al: Alpha thalassemia and stroke risk in sickle cell tion in sickle hemoglobinopathies. J Nucl Med 43(7):896–900, 2002.
anemia. Am J Hematol 45(4):279–282, 1994. 229. Lonergan G, Cline DB, Abbondanzo SL: Sickle cell anemia. Radiographics 21:971–994,
197. Adams R, McKie V, Nichols F, et al: The use of transcranial ultrasonography to predict 2001.
stroke in sickle cell disease. N Engl J Med 326(9):605–610, 1992. 230. Smith J: Bone disorders in sickle cell disease. Hematol Oncol Clin North Am 10:1
198. Berkelhammer LD, Williamson AL, Sanford SD, et al: Neurocognitive sequelae of pedi- 345–1356, 1996.
atric sickle cell disease: A review of the literature. Child Neuropsychol 13(2):120–131, 231. Atkins BL, Price EH, Tillyer L, et al: Salmonella osteomyelitis in sickle cell disease chil-
2007. dren in the east end of London. J Infect 34(2):133–138, 1997.
199. Fullerton HJ, Gardner M, Adams RJ, et al: Obstacles to primary stroke prevention in 232. Burnett MW, Bass JW, Cook BA: Etiology of osteomyelitis complicating sickle cell dis-
children with sickle cell disease. Neurology 67(6):1098–1099, 2006. ease. Pediatrics 101(2):296–297, 1998.
200. Fullerton HJ, Adams RJ, Zhao S, et al: Declining stroke rates in Californian children 233. William R, Hussein SS, Jeans WD, et al: A prospective study of soft-tissue ultrasonogra-
with sickle cell disease. Blood 104(2):336–339, 2004. phy in sickle cell disease patients with suspected osteomyelitis. Clin Radiol 55:307–310,
201. Hulbert ML, Scothorn DJ, Panepinto JA, et al: Exchange blood transfusion compared 2000.
with simple transfusion for first overt stroke is associated with a lower risk of subse- 234. Umans H, Haramati, N, Flusser G. The diagnostic role of gadolinium enhanced MRI
quent stroke: A retrospective cohort study of 137 children with sickle cell anemia. J in distinguishing between acute medullary bone infarct and osteomyelitis. Magn Reson
Pediatr 149(5):710–712, 2006. Imaging 18:255–262, 2000.
202. Vichinsky EP, Haberkern CM, Neumayr L, et al: A comparison of conservative and 235. Neonato M, Guilloud-Bataille M, Beauvais P, et al: Acute clinical events in 299 homozy-
aggressive transfusion regimens in the perioperative management of sickle cell dis- gous sickle cell patients living in France. French study group on sickle cell disease. Eur
ease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med J Haematol 65:155–164, 2000.
333(4):206–213, 1995. 236. Guggenbuhl P, Fergelot P, Doyard M, et al: Bone status in a mouse model of genetic
203. Zimmerman SA, Schultz WH, Burgett S, et al: Hydroxyurea therapy lowers transcranial hemochromatosis. Osteoporos Int 22(8):2313–2319, 2011.
Doppler flow velocities in children with sickle cell anemia. Blood 110(3):1043–1047, 237. Tsay J, Yang Z, Ross FP, et al: Bone loss caused by iron overload in a murine model:
2007. Importance of oxidative stress. Blood 116(14):2582–2589, 2010.
204. Ware RE, Helms RW, SWiTCH Investigators: Stroke With Transfusions Changing to 238. Fung EB, Harmatz PR, Milet M, et al: Fracture prevalence and relationship to endo-
Hydroxyurea (SWiTCH). Blood 119(17):3925–3932, 2012. crinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone
205. Dobson SR, Holden KR, Nietert PJ, et al: Moyamoya syndrome in childhood sickle 43(1):162–168, 2008.
cell disease: A predictive factor for recurrent cerebrovascular events. Blood 99(9):3144– 239. Osunkwo I, Ziegler TR, Alvarez J, et al: High dose vitamin D therapy for chronic pain in
3150, 2002. children and adolescents with sickle cell disease: Results of a randomized double blind
206. Hankinson TC, Bohman LE, Heyer G, et al: Surgical treatment of moyamoya syndrome pilot study. Br J Haematol 159(2):211–215, 2012.
in patients with sickle cell anemia: Outcome following encephaloduroarteriosynangio- 240. Milner P, Kraus AP, Sebes JJ, et al: Sickle cell disease as a cause of osteonecrosis of the
sis. J Neurosurg Pediatr 1(3):211–216, 2008. femoral head. N Engl J Med 325:1479–1481, 1991.
207. Nur E, Biemond BJ, Otten HM, et al: Oxidative stress in sickle cell disease; pathophys- 241. Ware H, Brooks AP, Toye R, Berney SI: Sickle cell disease and silent avascular necrosis
iology and potential implications for disease management. Am J Hematol 86(6):484– of the hip. J Bone Joint Surg Br 73:947–949, 1991.
489, 2011. 242. Adekile AD, Gupta R, Yacoub F, et al: Avascular necrosis of the hip in children with
208. Sklar AH, Campbell H, Caruana RJ, et al: A population study of renal function in sickle sickle cell disease and high Hb F: Magnetic resonance imaging findings and influence
cell anemia. Int J Artif Organs 13(4):231–236, 1990. of alpha-thalassemia trait. Acta Haematol 105(1):27–31, 2001.
209. Falk RJ, Scheinman J, Phillips G, et al: Prevalence and pathologic features of sickle cell 243. Mahadeo KM, Oyeku S, Taragin B, et al: Increased prevalence of osteonecrosis of
nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J the femoral head in children and adolescents with sickle-cell disease. Am J Hematol
Med 326(14):910–915, 1992. 86(9):806–808, 2011.

Kaushansky_chapter 49_p0759-0788.indd 785 9/18/15 3:02 PM